Infliximab and Tofacitinib Together for Acute Severe Ulcerative Colitis
Tests infliximab with tofacitinib in adults hospitalized with severe ulcerative colitis.
Plain-language title generated from the registry record
Registry title: Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial
Key facts
- Where
- Hyderabad, IndiaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07297069, who can take part
Where in India
- Asian Institute Of GastroenterologyHyderabad, IndiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Asian Institute of Gastroenterology, India
- Trial code
- NCT07297069
- Record updated
- 24 December 2025
- Original description
In adults hospitalized with acute severe ulcerative colitis who fail to respond to intravenous steroids, does treatment with a combination of infliximab and tofacitinib, compared with infliximab alone or tofacitinib alone, result in higher rates of early clinical remission and mucosal healing, and fewer treatment-related complications over a 10 week periodRead full original descriptionShow less
Combination of INFLIXIMAB With TOFACITINIB in ASUC - CINTO Trial
In adults hospitalized with acute severe ulcerative colitis who fail to respond to intravenous steroids, does treatment with a combination of infliximab and tofacitinib, compared with infliximab alone or tofacitinib alone, result in higher rates of early clinical remission and mucosal healing, and fewer treatment-related complications over a 10 week period
Inclusion: Adult (aged 18 years to 65 years) patients hospitalised due to ASUC.
Exclusion: Pseudomembranous colitis or concomitant CMV colitis; Latent or active tuberculosis; Intestinal perforation; Massive haemorrhage requiring emergency colectomy; Current diagnosis or history of thromboembolic disease patients with severe cardiorespiratory, renal or hepatic Co morbidities; Patients with UC who did not meet the Truelove Witts criteria for ASUC; Patients who are already on Tofacitinib / Infliximab; Crohn's or Indeterminate colitis; Mega colon (if the diameter of the transverse colon is 5.5 cm or more, with apparent oedema of the bowel wall on plain abdominal radiographs); Pregnant or lactating female individuals.